查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1979983

人工智慧神经诊断市场预测：至 2034 年—按产品、技术、应用、最终用户和地区分類的全球分析

AI Neurodiagnostics Market Forecasts to 2034 - Global Analysis By Product, Technology, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的研究，预计到 2026 年，全球 AI 神经诊断市场将达到 182 亿美元，并在预测期内以 4.5% 的复合年增长率成长，到 2034 年达到 259 亿美元。

人工智慧神经诊断是指利用人工智慧分析脑部相关数据并侦测神经系统疾病的技术。透过处理扫描影像、生物讯号和患者记录，人工智慧系统可以识别与失智症、痴呆症和中风等疾病相关的模式。这些工具提高了医生诊断的准确性和速度，有助于优化治疗方案并改善患者预后。透过提供预测性见解并减少人为错误，这项技术增强了传统方法，代表了医学领域的一项前景广阔的进步，融合了神经科学和机器学习。

神经系统疾病盛行率上升

阿兹海默症、帕金森氏症、癫痫和中风等神经系统疾病发病率的不断上升，是人工智慧神经诊断市场的主要成长要素。全球人口老化和生活方式相关的风险因素正在扩大需要先进诊断解决方案的患者群体。对早期准确检测的需求促使医疗机构采用人工智慧驱动的神经影像和预测分析工具。这些技术在提高诊断准确性的同时，也能缩短影像解读时间。此外，不断上涨的医疗成本和公众意识的提高也在推动市场扩张。因此，神经系统疾病负担的加重正在显着加速人工智慧神经诊断技术的应用。

临床检验及核准延误

漫长的临床检验过程和监管核准要求对商业化构成重大障碍。基于人工智慧的神经系统诊断解决方案必须透过广泛的测试来证明其高精度、高重复性和安全性。监管机构制定了严格的合规标准，并延长了产品上市时间。此外，不断发展的人工智慧管治框架也为开发者带来了不确定性。小规模公司在漫长的检验週期中往往面临沉重的财务负担。因此，儘管技术取得了显着进步，但核准延迟和复杂的认证流程阻碍了产品快速进入市场。

疾病早期检测平台

新兴的人工智慧驱动型早期检测平台蕴藏着变革性的成长机会。先进的演算法能够在临床症状出现之前，识别神经影像数据中细微的生物标记。在预防性医疗策略的推动下，医疗服务提供者正优先考虑能够实现主动介入的工具。与穿戴式装置和电子健康记录的整合提高了预测模型的准确性。製药公司也正在利用这些平台优化临床试验。随着医疗体係向价值导向型医疗模式转型，早期检测能力蕴藏着巨大的商业性和临床潜力。

资料隐私合规风险

资料隐私法规对人工智慧神经诊断系统的部署构成重大威胁。这些系统依赖大规模的患者资料集，其中包括敏感的神经影像记录。诸如 HIPAA 和 GDPR 等严格的资料保护法要求企业建立严密的合规机制。违规行为可能导致经济处罚和声誉损害。此外，跨境资料传输的限制也使跨国公司的营运变得更加复杂。因此，网路安全漏洞和监管风险仍然是参与企业市场时面临的持续挑战。

新冠疫情的影响：

新冠疫情初期，由于就诊量减少和选择性筛检测试延迟，神经学诊断流程受到干扰。由于医疗系统优先保障急诊，人工智慧解决方案的应用一度放缓。然而，疫情加速了数位化医疗转型和远距离诊断能力的提升。在医护人员短缺的情况下，远距神经病学和人工智慧辅助影像诊断的重要性日益凸显。医疗IT基础设施投资的增加进一步推动了人工智慧的整合。疫情后的復苏正在增强对自动化、可扩展的神经系统诊断平台的长期需求。

在预测期内，基于人工智慧的神经影像软体领域预计将占据最大的市场份额。

在预测期内，基于人工智慧的神经影像软体预计将占据最大的市场份额。这些解决方案能够以极高的精确度和速度分析MRI、CT和PET扫描影像。医院和诊断中心对自动化影像分析的日益依赖，巩固了该领域的领先地位。随着影像检查量的增加，临床医生正在寻求工作流程优化工具。演算法的不断改进提高了肿瘤、病变和退化性病变的检测准确性。只要影像检查在神经系统疾病诊断中继续发挥核心作用，该领域在收入方面就将保持主导。

预计在预测期内，深度学习和神经网路领域将实现最高的复合年增长率。

在预测期内，深度学习和神经网路领域预计将呈现最高的成长率。先进的神经网路架构能够对复杂的脑部资料进行卓越的模式识别和异常检测。随着运算能力的提升和大规模标註资料集数量的成长，其效能能力也不断增强。这些模型有助于预测分析和疾病进展建模。合作研究进一步加速了创新。因此，深度学习技术已成为人工智慧神经诊断市场中成长最快的技术基础。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额。该地区强大的医疗保健基础设施和人工智慧驱动型医疗技术的高普及率是其主导地位的基石。强劲的研发投入和领先的人工智慧医疗公司的存在正在加速商业化进程。有利的报销政策进一步促进了人工智慧技术融入临床工作流程。此外，神经系统疾病盛行率的不断上升也增强了市场需求。随着创新生态系统的日趋成熟，北美将继续成为重要的收入来源。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率。医疗保健的快速数位化和医院网路的扩张正在推动该地区的成长。各国政府正在加大对人工智慧创新和医学影像基础设施的投资。在患者数量激增和人们对神经系统疾病意识提升的推动下，对可扩展诊断技术的需求正在加速增长。在新兴经济体，经济高效的人工智慧平台正被广泛采用，以应对专科医生短缺的问题。因此，亚太地区脱颖而出，成为成长最快的区域市场。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要参与者（最多3家公司）的SWOT分析
  • 区域细分
    • 主要国家的市场估算和预测，以及根据客户需求量身定制的复合年增长率（註：需要进行可行性测试）。
  • 竞争性标竿分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球人工智慧神经诊断市场：按产品划分

  • 基于人工智慧的神经影像软体
  • 脑电图分析平台
  • 脑监测系统
  • 临床决策支援系统
  • 基于云端的神经学诊断平台
  • 即时神经学诊断设备
  • 穿戴式脑部监测设备

第六章 全球人工智慧神经诊断市场：依技术划分

  • 机器学习演算法
  • 深度学习与神经网络
  • 自然语言处理
  • 电脑视觉在神经影像学的应用
  • 巨量资料分析
  • 云端运算和边缘人工智慧运算

第七章 全球人工智慧神经诊断市场：按应用划分

  • 癫痫侦测
  • 阿兹海默症诊断
  • 帕金森氏症评估
  • 中风侦测与监测
  • 创伤性脑损伤（TBI）分析
  • 脑肿瘤的识别

第八章 全球人工智慧神经诊断市场：按最终用户划分

  • 医院和神经科科诊所
  • 诊断影像中心
  • 研究和学术机构
  • 远端医疗提供者
  • 门诊手术中心
  • 製药公司

第九章 全球人工智慧神经诊断市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十章 战略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十一章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十二章：公司简介

  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • Canon Medical Systems Corporation
  • Fujifilm Holdings Corporation
  • Medtronic plc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Compumedics Limited
  • Neurosoft LLC
  • BrainScope Company, Inc.
  • Butterfly Network, Inc.
  • iSchemaView, Inc.
  • Qure.ai Technologies Pvt. Ltd.
  • Aidoc Medical Ltd.
  • IBM Watson Health
  • Ceribell, Inc.
  • Advanced Brain Monitoring, Inc.
Product Code: SMRC34146

According to Stratistics MRC, the Global AI Neurodiagnostics Market is accounted for $18.2 billion in 2026 and is expected to reach $25.9 billion by 2034 growing at a CAGR of 4.5% during the forecast period. AI neurodiagnostics refers to the use of artificial intelligence to analyze brain-related data for detecting neurological conditions. By processing scans, signals, and patient records, AI systems can identify patterns linked to disorders such as epilepsy, dementia, or stroke. These tools assist doctors in making faster and more accurate diagnoses, improving treatment planning and patient outcomes. The technology enhances traditional methods by offering predictive insights and reducing human error, making it a promising advancement in healthcare that bridges neuroscience and machine learning.

Market Dynamics:

Driver:

Rising neurological disorder prevalence

The increasing incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke is a primary growth catalyst for the AI Neurodiagnostics Market. Aging global demographics and lifestyle-related risk factors are expanding the patient pool requiring advanced diagnostic solutions. Fueled by the need for early and accurate detection, healthcare providers are adopting AI-enabled neuroimaging and predictive analytics tools. These technologies enhance diagnostic precision while reducing interpretation time. Moreover, rising healthcare expenditure and awareness campaigns further support market expansion. Consequently, growing neurological disease burden significantly accelerates AI neurodiagnostic adoption.

Restraint:

Clinical validation and approval delays

Lengthy clinical validation processes and regulatory approval requirements present substantial barriers to commercialization. AI-based neurodiagnostic solutions must demonstrate high accuracy, reproducibility, and safety through extensive trials. Regulatory agencies impose strict compliance standards, prolonging time-to-market. Additionally, evolving AI governance frameworks create uncertainty for developers. Smaller firms often face financial strain during prolonged validation cycles. Therefore, delayed approvals and complex certification pathways restrain rapid market penetration despite strong technological advancements.

Opportunity:

Early-stage disease detection platforms

Emerging AI-powered early detection platforms offer transformative growth opportunities. Advanced algorithms can identify subtle biomarkers in neuroimaging data before clinical symptoms manifest. Spurred by preventive healthcare strategies, providers are prioritizing tools that enable proactive intervention. Integration with wearable devices and electronic health records enhances predictive modeling accuracy. Pharmaceutical companies also leverage these platforms for clinical trial optimization. As healthcare systems shift toward value-based care, early-stage detection capabilities create substantial commercial and clinical potential.

Threat:

Data privacy compliance risks

Data privacy regulations pose a critical threat to AI neurodiagnostic deployment. These systems rely on large-scale patient datasets, including sensitive neurological imaging records. Stringent data protection laws such as HIPAA and GDPR mandate rigorous compliance frameworks. Non-compliance can result in financial penalties and reputational damage. Additionally, cross-border data transfer restrictions complicate multinational operations. Consequently, cybersecurity vulnerabilities and regulatory risks remain persistent challenges for market participants.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted neurological diagnostic procedures due to reduced hospital visits and deferred elective screenings. Healthcare systems prioritized emergency care, temporarily slowing AI solution adoption. However, the pandemic accelerated digital health transformation and remote diagnostic capabilities. Tele-neurology and AI-assisted imaging interpretation gained traction amid workforce shortages. Increased investment in healthcare IT infrastructure further supported AI integration. Post-pandemic recovery has strengthened long-term demand for automated, scalable neurodiagnostic platforms.

The AI-based neuroimaging softwaresegment is expected to be the largest during the forecast period

The AI-based neuroimaging software segment is expected to account for the largest market share during the forecast period. These solutions analyze MRI, CT, and PET scans with enhanced accuracy and speed. Growing reliance on automated imaging interpretation in hospitals and diagnostic centers underpins segment dominance. Influenced by rising imaging volumes, clinicians seek workflow optimization tools. Continuous algorithm refinement improves detection of tumors, lesions, and degenerative patterns. As imaging remains central to neurological diagnosis, this segment sustains revenue leadership.

The deep learning & neural networkssegment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep learning & neural networks segment is predicted to witness the highest growth rate. Advanced neural architectures enable superior pattern recognition and anomaly detection in complex brain data. Propelled by increasing computational power and large annotated datasets, performance capabilities continue to expand. These models facilitate predictive analytics and disease progression modeling. Research collaborations further accelerate innovation. Consequently, deep learning technologies represent the fastest-growing technological backbone within the AI Neurodiagnostics Market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. Robust healthcare infrastructure and high adoption of AI-driven medical technologies support regional dominance. Strong R&D investments and presence of leading AI healthcare firms accelerate commercialization. Favorable reimbursement policies further encourage integration into clinical workflows. Additionally, increasing neurological disease prevalence strengthens demand. As innovation ecosystems mature, North America remains the primary revenue contributor.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Rapid healthcare digitization and expanding hospital networks drive regional growth. Governments are investing in AI innovation and medical imaging infrastructure. Propelled by large patient populations and rising neurological awareness, demand for scalable diagnostics is accelerating. Emerging economies are adopting cost-efficient AI platforms to address specialist shortages. Therefore, Asia Pacific stands out as the fastest-growing regional market.

Key players in the market

Some of the key players in AI Neurodiagnostics Market include GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Medtronic plc, Natus Medical Incorporated, Nihon Kohden Corporation, Compumedics Limited, Neurosoft LLC, BrainScope Company, Inc., Butterfly Network, Inc., iSchemaView, Inc., Qure.ai Technologies Pvt. Ltd., Aidoc Medical Ltd., IBM Watson Health, Ceribell, Inc., and Advanced Brain Monitoring, Inc.

Key Developments:

In February 2026, Qure.ai Technologies Pvt. Ltd. announced enhancements to its AI stroke triage platform, enabling faster detection of large vessel occlusions in emergency departments, improving time-to-treatment outcomes.

In January 2026, Aidoc Medical Ltd. launched its AI Neuro Suite expansion, adding modules for intracranial hemorrhage detection and workflow prioritization, strengthening its role in acute care diagnostics.

In November 2025, Butterfly Network, Inc. introduced AI-powered portable brain imaging capabilities on its handheld ultrasound devices, targeting point-of-care neurodiagnostics in rural and resource-limited settings.

Products Covered:

  • AI-Based Neuroimaging Software
  • EEG Analytics Platforms
  • Brain Monitoring Systems
  • Clinical Decision Support Systems
  • Cloud-Based Neurodiagnostic Platforms
  • Point-of-Care Neurodiagnostic Devices
  • Wearable Brain Monitoring Devices

Technologies Covered:

  • Machine Learning Algorithms
  • Deep Learning & Neural Networks
  • Natural Language Processing
  • Computer Vision in Neuroimaging
  • Big Data Analytics
  • Cloud & Edge AI Computing

Applications Covered:

  • Epilepsy Detection
  • Alzheimer's Disease Diagnosis
  • Parkinson's Disease Assessment
  • Stroke Detection & Monitoring
  • Traumatic Brain Injury (TBI) Analysis
  • Brain Tumor Identification

End Users Covered:

  • Hospitals & Neurology Clinics
  • Diagnostic Imaging Centers
  • Research & Academic Institutes
  • Telemedicine Providers
  • Ambulatory Surgical Centers
  • Pharmaceutical Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI Neurodiagnostics Market, By Product

  • 5.1 AI-Based Neuroimaging Software
  • 5.2 EEG Analytics Platforms
  • 5.3 Brain Monitoring Systems
  • 5.4 Clinical Decision Support Systems
  • 5.5 Cloud-Based Neurodiagnostic Platforms
  • 5.6 Point-of-Care Neurodiagnostic Devices
  • 5.7 Wearable Brain Monitoring Devices

6 Global AI Neurodiagnostics Market, By Technology

  • 6.1 Machine Learning Algorithms
  • 6.2 Deep Learning & Neural Networks
  • 6.3 Natural Language Processing
  • 6.4 Computer Vision in Neuroimaging
  • 6.5 Big Data Analytics
  • 6.6 Cloud & Edge AI Computing

7 Global AI Neurodiagnostics Market, By Application

  • 7.1 Epilepsy Detection
  • 7.2 Alzheimer's Disease Diagnosis
  • 7.3 Parkinson's Disease Assessment
  • 7.4 Stroke Detection & Monitoring
  • 7.5 Traumatic Brain Injury (TBI) Analysis
  • 7.6 Brain Tumor Identification

8 Global AI Neurodiagnostics Market, By End User

  • 8.1 Hospitals & Neurology Clinics
  • 8.2 Diagnostic Imaging Centers
  • 8.3 Research & Academic Institutes
  • 8.4 Telemedicine Providers
  • 8.5 Ambulatory Surgical Centers
  • 8.6 Pharmaceutical Companies

9 Global AI Neurodiagnostics Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 GE HealthCare Technologies Inc.
  • 12.2 Siemens Healthineers AG
  • 12.3 Koninklijke Philips N.V.
  • 12.4 Canon Medical Systems Corporation
  • 12.5 Fujifilm Holdings Corporation
  • 12.6 Medtronic plc
  • 12.7 Natus Medical Incorporated
  • 12.8 Nihon Kohden Corporation
  • 12.9 Compumedics Limited
  • 12.10 Neurosoft LLC
  • 12.11 BrainScope Company, Inc.
  • 12.12 Butterfly Network, Inc.
  • 12.13 iSchemaView, Inc.
  • 12.14 Qure.ai Technologies Pvt. Ltd.
  • 12.15 Aidoc Medical Ltd.
  • 12.16 IBM Watson Health
  • 12.17 Ceribell, Inc.
  • 12.18 Advanced Brain Monitoring, Inc.

List of Tables

  • Table 1 Global AI Neurodiagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI Neurodiagnostics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global AI Neurodiagnostics Market Outlook, By AI-Based Neuroimaging Software (2023-2034) ($MN)
  • Table 4 Global AI Neurodiagnostics Market Outlook, By EEG Analytics Platforms (2023-2034) ($MN)
  • Table 5 Global AI Neurodiagnostics Market Outlook, By Brain Monitoring Systems (2023-2034) ($MN)
  • Table 6 Global AI Neurodiagnostics Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
  • Table 7 Global AI Neurodiagnostics Market Outlook, By Cloud-Based Neurodiagnostic Platforms (2023-2034) ($MN)
  • Table 8 Global AI Neurodiagnostics Market Outlook, By Point-of-Care Neurodiagnostic Devices (2023-2034) ($MN)
  • Table 9 Global AI Neurodiagnostics Market Outlook, By Wearable Brain Monitoring Devices (2023-2034) ($MN)
  • Table 10 Global AI Neurodiagnostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 11 Global AI Neurodiagnostics Market Outlook, By Machine Learning Algorithms (2023-2034) ($MN)
  • Table 12 Global AI Neurodiagnostics Market Outlook, By Deep Learning & Neural Networks (2023-2034) ($MN)
  • Table 13 Global AI Neurodiagnostics Market Outlook, By Natural Language Processing (2023-2034) ($MN)
  • Table 14 Global AI Neurodiagnostics Market Outlook, By Computer Vision in Neuroimaging (2023-2034) ($MN)
  • Table 15 Global AI Neurodiagnostics Market Outlook, By Big Data Analytics (2023-2034) ($MN)
  • Table 16 Global AI Neurodiagnostics Market Outlook, By Cloud & Edge AI Computing (2023-2034) ($MN)
  • Table 17 Global AI Neurodiagnostics Market Outlook, By Application (2023-2034) ($MN)
  • Table 18 Global AI Neurodiagnostics Market Outlook, By Epilepsy Detection (2023-2034) ($MN)
  • Table 19 Global AI Neurodiagnostics Market Outlook, By Alzheimer's Disease Diagnosis (2023-2034) ($MN)
  • Table 20 Global AI Neurodiagnostics Market Outlook, By Parkinson's Disease Assessment (2023-2034) ($MN)
  • Table 21 Global AI Neurodiagnostics Market Outlook, By Stroke Detection & Monitoring (2023-2034) ($MN)
  • Table 22 Global AI Neurodiagnostics Market Outlook, By Traumatic Brain Injury (TBI) Analysis (2023-2034) ($MN)
  • Table 23 Global AI Neurodiagnostics Market Outlook, By Brain Tumor Identification (2023-2034) ($MN)
  • Table 24 Global AI Neurodiagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global AI Neurodiagnostics Market Outlook, By Hospitals & Neurology Clinics (2023-2034) ($MN)
  • Table 26 Global AI Neurodiagnostics Market Outlook, By Diagnostic Imaging Centers (2023-2034) ($MN)
  • Table 27 Global AI Neurodiagnostics Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 28 Global AI Neurodiagnostics Market Outlook, By Telemedicine Providers (2023-2034) ($MN)
  • Table 29 Global AI Neurodiagnostics Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 30 Global AI Neurodiagnostics Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.